fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Amoxicillin & clavulanic acid

All products: general benefit

Clavulin (BID) · DIN 02238831 · 200 mg & 28.5 mg/5 mL · suspension

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
1 brand, same coverage
Clavulin (BID) · DIN 02238831 Manufacturer: GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care; listing date 2000-01-17 Health Canada: Marketed since 2003-01-15 · brand CLAVULIN 200 · ATC J01CR02 AMOXICILLIN AND BETA-LACTAMASE INHIBITOR · form Powder for suspension · route Oral · ingredients AMOXICILLIN (AMOXICILLIN TRIHYDRATE) 200 MG/5ML, CLAVULANIC ACID (CLAVULANATE POTASSIUM) 28.5 MG/5ML · company Glaxosmithkline inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Ministry pays: $0.1007 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02238831)

Source record
DIN 02238831: Clavulin (BID) Raw flags: sec3=Y Item: 081216081; group id 26; item number 0050; lccId None; manufacturer id GSK Source form: Susp; strength: 200mg & 28.5mg/5mL Recorded listing: General benefit Source prices (unrounded): $0.1974; ministry $0.1007 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02238831 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=62269
Interchangeable products
Jamp Amoxi Clav Suspension · DIN 02539411 · $0.1007
Shortage status: resolved shortage (ended June 2, 2023); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02238831
Shortage record checked October 6, 2026

Other products in the same Health Canada class (J01C, J01CR): coverage varies; not interchangeable

  • Piperacillin + tazobactam (Tazocin): not a benefit
  • Amoxicillin (Novamoxin): general benefit, not a benefit, listing status unconfirmed
  • Ampicillin (Penbritin): general benefit, not a benefit
  • Cloxacillin (Orbenin): general benefit, not a benefit
  • Penicillin v (Nadopen-V): general benefit, not a benefit
Other drugs in the same formulary class (08:12:16 Penicillins) and how they are covered

Matched class: 08:12:16 Penicillins

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Some products covered without a code (check the product listing): AMOXICILLIN, AMPICILLIN, CLOXACILLIN, PENICILLIN V (POTASSIUM) 08:12:16 Penicillins

PIPERACILLIN SODIUM & TAZOBACTAM SODIUM

· 18 products · Off-Formulary Interchangeable, not an ODB benefit (16), Off-Formulary Interchangeable, not an ODB benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (2) · strengths: 2g & 250mg, 3g & 375mg, 4g & 500mg · Inj Pd-2.25g Vial Pk, Inj Pd-3.375g Vial Pk, Inj Pd-4.5g Vial Pk

AMOXICILLIN

· 36 products · General benefit (27), Listed, not a benefit (4), Off-Formulary Interchangeable, not an ODB benefit (4), Temporary benefit (1) · strengths: 250mg, 500mg, 125mg, 25mg/mL, 50mg/mL · Cap, Chew Tab, O/L, Pd for Oral Susp

AMPICILLIN

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 250mg, 500mg · Cap

CLOXACILLIN

· 8 products · Listed, not a benefit (3), General benefit (5) · strengths: 250mg, 500mg, 25mg/mL · Cap, O/L

PENICILLIN V (POTASSIUM)

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 25mg/mL, 300mg · O/L, Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 08:12:16
Full class listing Related classes: 08:12:04 Antifungals, 08:12:07 Carbapenems, 08:12:12 Erythromycins, 08:12:24 Tetracyclines, 08:12:28 Other Antibiotics, 08:14:08 Azoles Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: lower respiratory tract infections
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. CEFOXITIN SODIUM · Off-Formulary Interchangeable, not an ODB benefit 5 - Lower respiratory tract infections PM: https://pdf.hres.ca/dpd_pm/00073366.PDF; date November 16, 2023; DIN 02128187; fetched 2026-09-10 Product monograph CEFTRIAXONE DISODIUM · Listed, not a benefit (3), General benefit (9), General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (1), Off-Formulary Interchangeable, not an ODB benefit (3) • Lower Respiratory tract infections caused by E. coli, H. influenzae, K. pneumoniae and species, Staph. aureus, Strep. pneumoniae and species (excluding enterococci). PM: https://pdf.hres.ca/dpd_pm/00071552.PDF; date MAY 15, 2023; DIN 02289695; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-09-22
What the Health Canada label says it is for
1. Indications CLAVULIN (amoxicillin / clavulanate potassium) is indicated for the treatment of the following infections when caused by CLAVULIN-susceptible strains of the designated bacteria: • Sinusitis when caused by β-lactamase producing strains of H. influenzae or Moraxella (Branhamella) catarrhalis. • Otitis Media when caused by β-lactamase producing strains of H. influenzae or Moraxella (Branhamella) catarrhalis. • Lower Respiratory Tract Infections when caused by β-lactamase producing strains of H. influenzae, K. pneumoniae, S. aureus or Moraxella (Branhamella) catarrhalis. • Skin and Soft Tissue Infections when caused by β-lactamase producing strains of S. aureus. • Urinary Tract Infections when caused by β-lactamase producing strains of E. coli. While CLAVULIN is indicated only for the conditions listed above, infections caused by ampicillin (amoxicillin) susceptible organisms are also amenable to CLAVULIN treatment due to its amoxicillin content. Furthermore, mixed infections caused by organisms susceptible to ampicillin (amoxicillin) and β-lactamase producing organisms susceptible to CLAVULIN should not require the addition of another an… https://pdf.hres.ca/dpd_pm/00084428.PDF PM date: 2026-04-24 Source product: CLAVULIN 250 F ORAL SUS; DIN 01916874; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.